Egetis Therapeutics AB is an innovative and integrated pharmaceutical company, which engages in the development of new drugs for treatment of serious diseases. Its projects include Emcitate for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency. The company was founded by Torsten Almén, Heidi Brurok, Louis J. Ignarro, Per Jynge, Jan Olof Gustav Karlsson, Ingemar Lundström, and Rob Towart in 2006 and is headquartered in Stockholm, Sweden.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
52 week high is the highest price of a stock in the past 52 weeks, or one year. Egetis Therapeutics AB 52 week high is $1.12 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Egetis Therapeutics AB 52 week low is $0.6353 as of November 22, 2026.
Egetis Therapeutics AB stock price today is $1.12.
Egetis Therapeutics AB stock price yesterday was $1.12.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Egetis Therapeutics AB 50-day moving average is $0.9531.